Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
TG Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
TG Therapeutics and Novimmune Enter into Agreement 12
TG Therapeutics Enters into Research Agreement with Fast Forward 13
TG Therapeutics Enters into Agreement with University of Nebraska Medical Center 14
TG Therapeutics Extends its Option Agreement with Checkpoint Therapeutics 15
TG Therapeutics Enters into Agreement with Checkpoint Therapeutics to Develop and Commercialize Immuno-Oncology Targeted Antibodies 16
TG Therapeutics Enters Into Agreement With Rhizen Pharma To Develop PI3K Delta Inhibitor, TGR-1202 17
Licensing Agreements 19
TG Therapeutics Enters into Licensing Agreement with Jiangsu Hengrui 19
TG Therapeutics Amends its Licensing Agreement with Jubilant Biosys 20
TG Therapeutics Exercises Option for Licensing Agreement with Rhizen Pharma To Develop PI3K Delta Inhibitor, TGR-1202 21
Ligand Pharma Enters into Licensing Agreement with TG Therapeutics for IRAK-4 Inhibitor Program 23
TG Therapeutics Enters Into Licensing Agreement With Ildong Pharma For Ublituximab 24
TG Therapeutics Enters Into Licensing Agreement With LFB Biotechnologies And GTC Biotherapeutics For Ublituximab 25
Equity Offering 26
TG Therapeutics Raises USD57.5 Million in Underwritten Public Offering of Shares 26
TG Therapeutics Raises USD50 Million in Public Offering Of Common Stock 28
TG Therapeutics Completes Private Placement Of Shares For US$18 Million 29
TG Therapeutics Completes Underwriters’ Exercise Of Over-Allotment Option For Public Offering Of Shares For US$5.3 Million 30
Manhattan Pharma Completes Private Placement Of Shares For US$25 Million 32
TG Therapeutics Inc – Key Competitors 33
TG Therapeutics Inc – Key Employees 34
TG Therapeutics Inc – Locations And Subsidiaries 35
Head Office 35
Other Locations & Subsidiaries 35
Recent Developments 36
Financial Announcements 36
Aug 07, 2018: TG Therapeutics provides business update and reports second quarter 2018 financial results 36
Nov 08, 2017: TG Therapeutics Provides Business Update and Reports Third Quarter 2017 Financial Results 37
Aug 09, 2017: TG Therapeutics Provides Business Update and Reports Second Quarter 2017 Financial Results 38
May 05, 2017: TG Therapeutics Provides Business Update and Reports First Quarter 2017 Financial Results 40
Mar 10, 2017: TG Therapeutics Announces Fourth Quarter and Year-End 2016 Financial Results and Business Update 42
Corporate Communications 43
Jun 04, 2018: TG Therapeutics Names Adam Waldman As Chief Commercial Officer 43
Product News 44
06/26/2017: TG Therapeutics Recaps Data from Triple Combination Therapy Trials at the 22nd European Hematology Association Annual Congress 44
05/18/2017: TG Therapeutics Announces Clinical Data Presentations at the Upcoming 22nd European Hematology Association Annual Congress 46
Product Approvals 47
Jan 24, 2017: TG Therapeutics Announces Orphan Drug Designation for the Combination of TG-1101 and TGR-1202 for the Treatment of Diffuse Large B-cell Lymphoma 47
Jan 09, 2017: TG Therapeutics Announces Orphan Drug Designation for the Combination of TG-1101 and TGR-1202 for Treatment of Chronic Lymphocytic Leukemia 48
Clinical Trials 49
Jan 24, 2018: TG Therapeutics Announces Data Presentation at the Upcoming Third Annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2018 49
Dec 11, 2017: TG Therapeutics Announces Preclinical & Clinical Data Presentations at the 59th American Society of Hematology Annual Meeting 50
Dec 08, 2017: TG Therapeutics Recaps Data Presentations at the Upcoming 59th American Society of Hematology Annual Meeting 53
Nov 01, 2017: TG Therapeutics Announces Data Presentations at the Upcoming 59th American Society of Hematology Annual Meeting 55
Oct 26, 2017: TG Therapeutics Announces Updated Results from the Ongoing Phase 2 Study of TG-1101 (ublituximab) in Patients with Multiple Sclerosis at the 7th Joint ECTRIMS – ACTRIMS Meeting 57
Oct 16, 2017: TG Therapeutics Announces Completion of Full Enrollment in the UNITY-CLL Phase 3 Trial 58
Sep 05, 2017: TG Therapeutics Announces Completion of Target Enrollment in the UNITY-CLL Phase 3 Trial 59
Aug 10, 2017: TG Therapeutics Announces Successful Outcome from the First Pre-Planned Interim Analysis by Independent DSMB of the DLBCL Cohort in the UNITY-NHL Phase 2b Trial 60
Jun 15, 2017: TG Therapeutics Announces Follow-Up Data from the Triple Combination of TG-1101, TGR-1202, and Bendamustine in Patients with DLBCL and FL at the 14th International Conference on Malignant Lymphoma 61
May 23, 2017: TG Therapeutics Announces Successful Outcome from Pre-Planned Interim Analysis by Independent DSMB in the UNITY-CLL Phase 3 Trial 62
Other Significant Developments 63
May 08, 2018: TG Therapeutics Provides Business Update and Reports First Quarter 2018 Financial Results 63
Appendix 64
Methodology 64
About GlobalData 64
Contact Us 64
Disclaimer 64
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
TG Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
TG Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
TG Therapeutics and Novimmune Enter into Agreement 12
TG Therapeutics Enters into Research Agreement with Fast Forward 13
TG Therapeutics Enters into Agreement with University of Nebraska Medical Center 14
TG Therapeutics Extends its Option Agreement with Checkpoint Therapeutics 15
TG Therapeutics Enters into Agreement with Checkpoint Therapeutics to Develop and Commercialize Immuno-Oncology Targeted Antibodies 16
TG Therapeutics Enters Into Agreement With Rhizen Pharma To Develop PI3K Delta Inhibitor, TGR-1202 17
TG Therapeutics Enters into Licensing Agreement with Jiangsu Hengrui 19
TG Therapeutics Amends its Licensing Agreement with Jubilant Biosys 20
TG Therapeutics Exercises Option for Licensing Agreement with Rhizen Pharma To Develop PI3K Delta Inhibitor, TGR-1202 21
Ligand Pharma Enters into Licensing Agreement with TG Therapeutics for IRAK-4 Inhibitor Program 23
TG Therapeutics Enters Into Licensing Agreement With Ildong Pharma For Ublituximab 24
TG Therapeutics Enters Into Licensing Agreement With LFB Biotechnologies And GTC Biotherapeutics For Ublituximab 25
TG Therapeutics Raises USD57.5 Million in Underwritten Public Offering of Shares 26
TG Therapeutics Raises USD50 Million in Public Offering Of Common Stock 28
TG Therapeutics Completes Private Placement Of Shares For US$18 Million 29
TG Therapeutics Completes Underwriters' Exercise Of Over-Allotment Option For Public Offering Of Shares For US$5.3 Million 30
Manhattan Pharma Completes Private Placement Of Shares For US$25 Million 32
TG Therapeutics Inc, Key Competitors 33
TG Therapeutics Inc, Key Employees 34
TG Therapeutics Inc, Subsidiaries 35
List of Figures
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9